Sanofi request taken under advisement in Lovenox case; Lilly CEO cheers Indianapolis in ad;

@FiercePharma: Drug recalls hit all-time high in 2009. Story | Follow @FiercePharma

Special Report: The Top Counterfeit Drugs. Read now >>

> A federal judge took under advisement a request by Sanofi-Aventis SA to bar U.S. regulators from allowing sales of a lower-cost rival to its Lovenox blood thinner. U.S. District Judge Emmet Sullivan in Washington didn't say when he would rule after Sanofi had asked him to force the FDA to suspend its approval of the generic produced by Sandoz with Momenta Pharmaceuticals technology. Story

> John Lechleiter (photo), chairman and CEO of Eli Lilly, uses a prominent forum--a full-page advertisement in today's Indianapolis Star--to cheer on colleagues and a city. Article

> The U.S. Ambassador to Egypt, Margaret Scobey, signed a cooperative agreement on behalf of the U.S. Trade Development Agency (USTDA) for a grant of over half a million dollars to improve the supply and delivery of pharmaceutical products in Egypt. Ambassador Scobey was joined by Dr. Kamal Sabra, Assistant Minister of Health for Pharmaceutical Affairs, at a signing ceremony for the $557,704 grant at her residence in Cairo. U.S. Embassy release

> Share price of Bengaluru-based biotechnology firm, Biocon rose 3.27 per cent to Rs 341.50 at the end of Tuesday's trading session at the Bombay Stock Exchange. This despite the company's stated stand of no possible deal with Pfizer in the near future. Article

> A Pfizer unit is seeking to duck responsibility for two women's breast cancers linked to its Prempro menopause drug, a lawyer argued at the end of a trial. Item

> Aventis Pharma today said it expects to launch a prostate cancer drug by next year for which it is currently in the process of getting approval from the drug regulator DCGI. Article

> Eli Lilly, Pfizer, Elan, Bristol-Myers Squibb and other drug companies have been rushing to test drugs that block the protein deposits found in the brain of Alzheimer's disease patients called amyloid. All along, a small band of skeptics have worried that the amyloid theory is misguided. Now their worst fears have come true: Eli Lilly halted development of an Alzheimer's drug because it made the disease worse in tests on 2,600 patients. Story

> Advaxis and the University of Pennsylvania School of Veterinary Medicine have signed a veterinary clinical research study contract to treat osteosarcoma in companion dogs using Advaxis' technology. The studies will be led by Assistant Professor Dr. Nicola Mason. Advaxis release

Biotech News

  @FierceBiotech: Big Pharma takes on risk with biosimilar programs. Article | Follow @FierceBiotech

> BioMarin snares orphan drug upstart in $115 million buyout. Item

> Amarin picks Colin Stewart as president, CEO. Report

> Novartis options Quark program in $680 million pact. Article

> Lilly's Alzheimer's disaster spells trouble for entire class. Story

Medical Device News

 @FierceMedDev: Top ten Orthopedic procedures with the most problems. Article | Follow @FierceMedDev

> Biomet receives warning letter, gets tax abatement approved. News

> Study controls pace of quail embroyo's heart using light. Report

> Medtronic purchases Osteotech for $123 million. Item

> Report: Stryker has eye on $1.5B Boston Sci unit. Story

Drug Delivery News

> Dicerna gets $25 million validation of RNA delivery tech. Report

> 'Nanotox' research also has implications for nano drug delivery. Article

> NextWave, Tris Pharma help the medicine go down. Story

> Midatech, Monosol Rx file joint patent for thin film delivery of nanoparticles. Report

> Oregon just says no to e-cigarettes. News

> UT Austin licenses unique delivery technique for AMD. Article

And Finally... Roche released guidelines for company use of social media, saying that "social media's high speed, level of interactivity and global access to any information you publish merits particular consideration to the appropriate uses for these applications." Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.